Novel targets in head and neck cancer: Should we be optimistic?

Abstract

Head and neck squamous cell carcinomas have distinct mutation and copy-number profiles depending on human papilloma-virus status. Although several challenges remain in biomarker implementation and clinical trial feasibility, incorporating available genomic data will expedite the development of novel therapeutics and predictive biomarker-driven clinical trials.